{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:36:08Z","timestamp":1768318568320,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry for Innovation and Technology of Hungary"},{"name":"Ministry of Human Capacities of Hungary","award":["\u00daNKP-19-3-II"],"award-info":[{"award-number":["\u00daNKP-19-3-II"]}]},{"name":"National Research, Development and Innovation Fund of Hungary","award":["NVKP_16-1-2016-0017"],"award-info":[{"award-number":["NVKP_16-1-2016-0017"]}]},{"name":"National Research, Development and Innovation Office of Hungary","award":["K134939"],"award-info":[{"award-number":["K134939"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Whereas selective sodium-glucose cotransporter 2 (SGLT2) inhibitors consistently showed cardiovascular protective effects in large outcome trials independent of the presence of type 2 diabetes mellitus (T2DM), the cardiovascular effects of dual SGLT1\/2 inhibitors remain to be elucidated. Despite its clinical relevance, data are scarce regarding left ventricular (LV) SGLT1 expression in distinct heart failure (HF) pathologies. We aimed to characterize LV SGLT1 expression in human patients with end-stage HF, in context of the other two major glucose transporters: GLUT1 and GLUT4.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Control LV samples (Control, n\u2009=\u20099) were harvested from patients with preserved LV systolic function who went through mitral valve replacement. LV samples from HF patients undergoing heart transplantation (n\u2009=\u200971) were obtained according to the following etiological subgroups: hypertrophic cardiomyopathy (HCM, n\u2009=\u20097); idiopathic dilated cardiomyopathy (DCM, n\u2009=\u200912); ischemic heart disease without T2DM (IHD, n\u2009=\u200914), IHD with T2DM (IHD\u2009+\u2009T2DM, n\u2009=\u200911); and HF patients with cardiac resynchronization therapy (DCM:CRT, n\u2009=\u20099, IHD:CRT, n\u2009=\u20099 and IHD-T2DM:CRT, n\u2009=\u20099). We measured LV SGLT1, GLUT1 and GLUT4 gene expressions with qRT-PCR. The protein expression of SGLT1, and activating phosphorylation of AMP-activated protein kinase (AMPK\u03b1) and extracellular signal-regulated kinase 1\/2 (ERK1\/2) were quantified by western blotting. Immunohistochemical staining of SGLT1 was performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with controls, LV SGLT1 mRNA and protein expressions were significantly and comparably upregulated in HF patients with DCM, IHD and IHD\u2009+\u2009T2DM (all P\u2009&lt;\u20090.05), but not in HCM. LV SGLT1 mRNA and protein expressions positively correlated with LVEDD and negatively correlated with EF (all P\u2009&lt;\u20090.01). Whereas AMPK\u03b1 phosphorylation was positively associated with SGLT1 protein expression, ERK1\/2 phosphorylation showed a negative correlation (both P\u2009&lt;\u20090.01). Immunohistochemical staining revealed that SGLT1 expression\u00a0was predominantly confined to cardiomyocytes, and not fibrotic tissue. Overall, CRT was associated with reduction of LV SGLT1 expression, especially in patients with DCM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Myocardial LV SGLT1 is upregulated in patients with HF (except in those with HCM), correlates significantly with parameters of cardiac remodeling (LVEDD) and systolic function (EF), and is downregulated in DCM patients with CRT. The possible role of SGLT1 in LV remodeling needs to be elucidated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-020-01141-1","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T14:04:13Z","timestamp":1601474653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7728-4775","authenticated-orcid":false,"given":"Alex Ali","family":"Sayour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Ol\u00e1h","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mih\u00e1ly","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1lint Andr\u00e1s","family":"Barta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eszter M\u00e1ria","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00e1lm\u00e1n","family":"Benke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikl\u00f3s","family":"P\u00f3los","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"Harty\u00e1nszky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Radovits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"issue":"22","key":"1141_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u2013288.","journal-title":"N Engl J Med"},{"issue":"7","key":"1141_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1141_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"18","key":"1141_CR4","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140(18):1463\u201376.","journal-title":"Circulation"},{"issue":"21","key":"1141_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1141_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"15","key":"1141_CR7","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","volume":"72","author":"TA Zelniker","year":"2018","unstructured":"Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(15):1845\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1141_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2213-8587(17)30314-5","volume":"6","author":"RM Bell","year":"2018","unstructured":"Bell RM, Yellon DM. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. Lancet Diabetes Endocrinol. 2018;6(6):435\u20137.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1141_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa064","author":"M Packer","year":"2020","unstructured":"Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovasc Res. 2020. https:\/\/doi.org\/10.1093\/cvr\/cvaa064.","journal-title":"Cardiovasc Res."},{"issue":"4","key":"1141_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(4):435\u201347.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1141_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(4):422\u201334.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1141_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12933-019-0938-6","volume":"18","author":"M Packer","year":"2019","unstructured":"Packer M. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovasc Diabetol. 2019;18(1):129.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1141_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"M Packer","year":"2020","unstructured":"Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43(3):508\u201311.","journal-title":"Diabetes Care"},{"issue":"2","key":"1141_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.10631","volume":"90","author":"L Zhou","year":"2003","unstructured":"Zhou L, Cryan EV, D'Andrea MR, Belkowski S, Conway BR, Demarest KT. Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1). J Cell Biochem. 2003;90(2):339\u201346.","journal-title":"J Cell Biochem"},{"issue":"2","key":"1141_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","volume":"1","author":"J Chen","year":"2010","unstructured":"Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010;1(2):57\u201392.","journal-title":"Diabetes Ther"},{"key":"1141_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","volume":"243","author":"A Di Franco","year":"2017","unstructured":"Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target. Int J Cardiol. 2017;243:86\u201390.","journal-title":"Int J Cardiol"},{"issue":"2","key":"1141_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/eurjhf\/hfp191","volume":"12","author":"D von Lewinski","year":"2010","unstructured":"von Lewinski D, Gasser R, Rainer PP, Huber MS, Wilhelm B, Roessl U, et al. Functional effects of glucose transporters in human ventricular myocardium. Eur J Heart Fail. 2010;12(2):106\u201313.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1141_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cvr\/cvp190","volume":"84","author":"SK Banerjee","year":"2009","unstructured":"Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009;84(1):111\u20138.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"1141_CR19","doi-asserted-by":"publisher","first-page":"e0130605","DOI":"10.1371\/journal.pone.0130605","volume":"10","author":"Y Kashiwagi","year":"2015","unstructured":"Kashiwagi Y, Nagoshi T, Yoshino T, Tanaka TD, Ito K, Harada T, et al. Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. PLoS ONE. 2015;10(6):e0130605.","journal-title":"PLoS ONE"},{"key":"1141_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/JAHA.114.000899","volume":"3","author":"M Ramratnam","year":"2014","unstructured":"Ramratnam M, Sharma RK, Auria S, Lee SJ, Wang D, Huang XY, et al. Transgenic knockdown of cardiac sodium\/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J Am Heart Assoc. 2014;3:4.","journal-title":"J Am Heart Assoc."},{"issue":"1","key":"1141_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12933-019-0889-y","volume":"18","author":"A Yoshii","year":"2019","unstructured":"Yoshii A, Nagoshi T, Kashiwagi Y, Kimura H, Tanaka Y, Oi Y, et al. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity. Cardiovasc Diabetol. 2019;18(1):85.","journal-title":"Cardiovasc Diabetol"},{"key":"1141_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijcard.2016.12.083","volume":"230","author":"L Szablewski","year":"2017","unstructured":"Szablewski L. Glucose transporters in healthy heart and in cardiac disease. Int J Cardiol. 2017;230:70\u20135.","journal-title":"Int J Cardiol"},{"issue":"9","key":"1141_CR23","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","volume":"467","author":"I Vrhovac","year":"2015","unstructured":"Vrhovac I, Balen Eror D, Klessen D, Burger C, Breljak D, Kraus O, et al. Localizations of Na(+)-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. 2015;467(9):1881\u2013988.","journal-title":"Pflugers Arch"},{"issue":"9","key":"1141_CR24","doi-asserted-by":"publisher","first-page":"e002183","DOI":"10.1161\/JAHA.115.002183","volume":"4","author":"R Lambert","year":"2015","unstructured":"Lambert R, Srodulski S, Peng X, Margulies KB, Despa F, Despa S. Intracellular Na+ concentration ([Na+]i) is elevated in diabetic hearts due to enhanced Na+-glucose cotransport. J Am Heart Assoc. 2015;4(9):e002183.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"1141_CR25","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.2337\/dc12-2391","volume":"36","author":"D Polidori","year":"2013","unstructured":"Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154\u201361.","journal-title":"Diabetes Care"},{"issue":"1","key":"1141_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/jpet.116.232025","volume":"358","author":"R Ohgaki","year":"2016","unstructured":"Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, et al. Interaction of the sodium\/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther. 2016;358(1):94\u2013102.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1141_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","volume":"18","author":"CMA Cefalo","year":"2019","unstructured":"Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019;18(1):20.","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"1141_CR28","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.jacc.2018.07.061","volume":"72","author":"SB Seidelmann","year":"2018","unstructured":"Seidelmann SB, Feofanova E, Yu B, Franceschini N, Claggett B, Kuokkanen M, et al. Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk. J Am Coll Cardiol. 2018;72(15):1763\u201373.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"1141_CR29","doi-asserted-by":"publisher","first-page":"e013389","DOI":"10.1161\/JAHA.119.013389","volume":"8","author":"CSP Lam","year":"2019","unstructured":"Lam CSP, Chandramouli C, Ahooja V, Verma S. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. J Am Heart Assoc. 2019;8(20):e013389.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"1141_CR30","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00424-020-02444-8","volume":"472","author":"L Bertrand","year":"2020","unstructured":"Bertrand L, Auquier J, Renguet E, Ange M, Cumps J, Horman S, et al. Glucose transporters in cardiovascular system in health and disease. Pflugers Arch. 2020;472(9):1385\u201399.","journal-title":"Pflugers Arch"},{"key":"1141_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3389\/fphys.2019.00690","volume":"10","author":"J Simon","year":"2019","unstructured":"Simon J, Nemeth E, Nemes A, Husveth-Toth M, Radovits T, Foldes G, et al. Circulating relaxin-1 level is a surrogate marker of myocardial fibrosis in HFrEF. Front Physiol. 2019;10:690.","journal-title":"Front Physiol"},{"key":"1141_CR32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cellsig.2018.08.010","volume":"51","author":"A Palvolgyi","year":"2018","unstructured":"Palvolgyi A, Simpson J, Bodnar I, Biro J, Palkovits M, Radovits T, et al. Auto-inhibition of adenylyl cyclase 9 (AC9) by an isoform-specific motif in the carboxyl-terminal region. Cell Signal. 2018;51:266\u201375.","journal-title":"Cell Signal"},{"issue":"6","key":"1141_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jacc.2010.11.010","volume":"57","author":"JL Hall","year":"2011","unstructured":"Hall JL, Fermin DR, Birks EJ, Barton PJ, Slaughter M, Eckman P, et al. Clinical, molecular, and genomic changes in response to a left ventricular assist device. J Am Coll Cardiol. 2011;57(6):641\u201352.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1141_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacc.2007.07.087","volume":"51","author":"M Vanderheyden","year":"2008","unstructured":"Vanderheyden M, Mullens W, Delrue L, Goethals M, de Bruyne B, Wijns W, et al. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol. 2008;51(2):129\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1141_CR35","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1096\/fj.201601031RR","volume":"31","author":"M Reiman","year":"2017","unstructured":"Reiman M, Laan M, Rull K, Sober S. Effects of RNA integrity on transcript quantification by total RNA sequencing of clinically collected human placental samples. FASEB J. 2017;31(8):3298\u2013308.","journal-title":"FASEB J"},{"issue":"1","key":"1141_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","volume":"17","author":"AA Sayour","year":"2019","unstructured":"Sayour AA, Korkmaz-Icoz S, Loganathan S, Ruppert M, Sayour VN, Olah A, et al. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med. 2019;17(1):127.","journal-title":"J Transl Med"},{"issue":"10166","key":"1141_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"2","key":"1141_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/cvr\/cvy295","volume":"115","author":"KL Chin","year":"2019","unstructured":"Chin KL, Ofori-Asenso R, Hopper I, von Lueder TG, Reid CM, Zoungas S, et al. Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. Cardiovasc Res. 2019;115(2):266\u201376.","journal-title":"Cardiovasc Res"},{"key":"1141_CR39","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","volume":"9","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Schumacher CA, Fiolet JWT, Kuschma MC, Hollmann MW, et al. Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol. 2018;9:1575.","journal-title":"Front Physiol"},{"issue":"11","key":"1141_CR40","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cvr\/cvz037","volume":"115","author":"Z Li","year":"2019","unstructured":"Li Z, Agrawal V, Ramratnam M, Sharma RK, D'Auria S, Sincoular A, et al. Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia\/reperfusion injury. Cardiovasc Res. 2019;115(11):1646\u201358.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"1141_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jphs.2019.11.001","volume":"142","author":"Y Sawa","year":"2020","unstructured":"Sawa Y, Saito M, Ishida N, Ibi M, Matsushita N, Morino Y, et al. Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice. J Pharmacol Sci. 2020;142(1):16\u201325.","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"1141_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12933-018-0741-9","volume":"17","author":"KA Connelly","year":"2018","unstructured":"Connelly KA, Zhang Y, Desjardins JF, Thai K, Gilbert RE. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. Cardiovasc Diabetol. 2018;17(1):99.","journal-title":"Cardiovasc Diabetol"},{"key":"1141_CR43","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","volume":"104","author":"TM Lee","year":"2017","unstructured":"Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298\u2013310.","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"1141_CR44","doi-asserted-by":"publisher","first-page":"F1201","DOI":"10.1152\/ajprenal.00111.2019","volume":"316","author":"J Nespoux","year":"2019","unstructured":"Nespoux J, Patel R, Hudkins KL, Huang W, Freeman B, Kim YC, et al. Gene deletion of the Na(+)-glucose cotransporter SGLT1 ameliorates kidney recovery in a murine model of acute kidney injury induced by ischemia-reperfusion. Am J Physiol Renal Physiol. 2019;316(6):F1201\u2013F12101210.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"1141_CR45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/cvr\/cvr230","volume":"92","author":"M Balteau","year":"2011","unstructured":"Balteau M, Tajeddine N, de Meester C, Ginion A, Des Rosiers C, Brady NR, et al. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res. 2011;92(2):237\u201346.","journal-title":"Cardiovasc Res"},{"issue":"5","key":"1141_CR46","first-page":"6887","volume":"17","author":"L Meng","year":"2018","unstructured":"Meng L, Uzui H, Guo H, Tada H. Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts. Mol Med Rep. 2018;17(5):6887\u2013922.","journal-title":"Mol Med Rep"},{"issue":"4","key":"1141_CR47","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.yjmcc.2010.06.003","volume":"49","author":"SK Banerjee","year":"2010","unstructured":"Banerjee SK, Wang DW, Alzamora R, Huang XN, Pastor-Soler NM, Hallows KR, et al. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. J Mol Cell Cardiol. 2010;49(4):683\u201392.","journal-title":"J Mol Cell Cardiol"},{"issue":"11","key":"1141_CR48","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/j.1440-1681.2009.05243.x","volume":"36","author":"XM Li","year":"2009","unstructured":"Li XM, Ma YT, Yang YN, Liu F, Chen BD, Han W, et al. Downregulation of survival signalling pathways and increased apoptosis in the transition of pressure overload-induced cardiac hypertrophy to heart failure. Clin Exp Pharmacol Physiol. 2009;36(11):1054\u201361.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"10","key":"1141_CR49","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1097\/HJH.0b013e32828626e2","volume":"25","author":"A Gonzalez","year":"2007","unstructured":"Gonzalez A, Ravassa S, Loperena I, Lopez B, Beaumont J, Querejeta R, et al. Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. J Hypertens. 2007;25(10):2148\u201357.","journal-title":"J Hypertens"},{"issue":"5","key":"1141_CR50","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1536\/ihj.17-565","volume":"59","author":"N Matsushita","year":"2018","unstructured":"Matsushita N, Ishida N, Ibi M, Saito M, Sanbe A, Shimojo H, et al. Chronic pressure overload induces cardiac hypertrophy and fibrosis via increases in SGLT1 and IL-18 gene expression in mice. Int Heart J. 2018;59(5):1123\u201333.","journal-title":"Int Heart J"},{"issue":"2","key":"1141_CR51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/jcp.10438","volume":"199","author":"H Jae Han","year":"2004","unstructured":"Jae Han H, Yeong Park J, Jung Lee Y, Taub M. Epidermal growth factor inhibits 14C-alpha-methyl-d-glucopyranoside uptake in renal proximal tubule cells: involvement of PLC\/PKC, p44\/42 MAPK, and cPLA2. J Cell Physiol. 2004;199(2):206\u201316.","journal-title":"J Cell Physiol"},{"issue":"4","key":"1141_CR52","doi-asserted-by":"publisher","first-page":"F634","DOI":"10.1152\/ajprenal.00217.2003","volume":"286","author":"HJ Han","year":"2004","unstructured":"Han HJ, Park SH, Lee YJ. Signaling cascade of ANG II-induced inhibition of alpha-MG uptake in renal proximal tubule cells. Am J Physiol Renal Physiol. 2004;286(4):F634\u2013F642642.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1141_CR53","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1038\/sj.ki.5002383","volume":"106","author":"YJ Lee","year":"2007","unstructured":"Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na(+)\/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl. 2007;106:S27\u201335.","journal-title":"Kidney Int Suppl"},{"issue":"16","key":"1141_CR54","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1161\/01.CIR.0000034049.61181.F3","volume":"106","author":"R Liao","year":"2002","unstructured":"Liao R, Jain M, Cui L, D'Agostino J, Aiello F, Luptak I, et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 2002;106(16):2125\u201331.","journal-title":"Circulation"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01141-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-020-01141-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01141-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:35:39Z","timestamp":1632962139000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01141-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01141-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"22 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The procedure of sample procurement was reviewed and approved by the institutional and national ethics committee (ethical permission numbers: ETT TUKEB 7891\/2012\/EKU (119\/PI\/12.) and TUKEB 73\/2005.). Informed consent from patients was obtained prior to surgery in all cases, conforming to the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}